Mechanism of action and resistance to monoclonal antibody therapy

被引：61

作者：

Villamor, N

Montserrat, E

Colomer, D

机构：

[1] Hosp Clin Barcelona, Inst Clin Malalties Hematol & Oncol, Unitat Hematopatol, Barcelona 08036, Spain

[2] Hosp Clin Barcelona, Inst Clin Malalties Hematol & Oncol, Hematol Serv, Barcelona 08036, Spain

[3] Inst Invest Biomed August Pi i Sunyer, Barcelona, Spain

来源：

SEMINARS IN ONCOLOGY | 2003年 / 30卷 / 04期

关键词：

CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; NON-HODGKINS-LYMPHOMA; FC-GAMMA-RIIIA; COMPLEMENT-MEDIATED LYSIS; CYTOKINE-RELEASE SYNDROME; RITUXIMAB IN-VITRO; B-CELL LYMPHOMA; TARGETED CHEMOTHERAPY; CAMPATH-1; ANTIGEN;

D O I：

10.1016/S0093-7754(03)00261-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Monoclonal antibodies (MoAbs) are increasingly used in the treatment of patients with hematological malignancies and autoimmune diseases. The most commonly employed humanized and chimeric MoAbs are rituximab, alemtuzumab (Campath-IH, Ilex Pharmaceuticals, San Antonio, TX), and gemtuzumab-ozogamicin (Mylotarg, Wyeth-Ayerst Laboratories, St Davids, PA). The mechanism of action of these antibodies, and host and cellular factors influencing the response, are not completely known. Induction of apoptosis, antibody-dependent cell cytotoxicity (ADCC), and complement-mediated cell death (CDC) is the proposed mechanism of action of these antibodies. We review the current understanding of the mechanism of action of and resistance to these MoAbs. © 2003 Elsevier Inc. All rights reserved.

引用

收藏

页码：424 / 433

页数：10

相关论文

共 89 条

[1]

Alas S, 2001, CLIN CANCER RES, V7, P709

[2] Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3 [J].

Amico, D ;

Barbui, AM ;

Erba, E ;

Rambaldi, A ;

Introna, M ;

Golay, J .

BLOOD, 2003, 101 (11) :4589-4597

[3] Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma [J].

Anderson, DR ;

GrilloLopez, A ;

Varns, C ;

Chambers, KS ;

Hanna, N .

BIOCHEMICAL SOCIETY TRANSACTIONS, 1997, 25 (02) :705-708

[4] EXPRESSION OF HUMAN B CELL-ASSOCIATED ANTIGENS ON LEUKEMIAS AND LYMPHOMAS - A MODEL OF HUMAN B-CELL DIFFERENTIATION [J].

ANDERSON, KC ;

BATES, MP ;

SLAUGHENHOUPT, BL ;

PINKUS, GS ;

SCHLOSSMAN, SF ;

NADLER, LM .

BLOOD, 1984, 63 (06) :1424-1433

[5] The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus [J].

Anolik, JH ;

Campbell, D ;

Felgar, RE ;

Young, F ;

Sanz, I ;

Rosenblatt, J ;

Looney, RJ .

ARTHRITIS AND RHEUMATISM, 2003, 48 (02) :455-459

[6] Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: Relationship to in vivo rituximab resistance [J].

Bannerji, R ;

Kitada, S ;

Flinn, IW ;

Pearson, M ;

Young, D ;

Reed, JC ;

Byrd, JC .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1466-1471

[7] Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species [J].

Bellosillo, B ;

Villamor, N ;

López-Guillermo, A ;

Marcé, S ;

Esteve, J ;

Campo, E ;

Colomer, D ;

Montserrat, E .

BLOOD, 2001, 98 (09) :2771-2777

[8] Phenotypic transformation of CD52pos to CD52neg leukemic T cells as a mechanism for resistance to CAMPATH-1H [J].

Birhiray, RE ;

Shaw, G ;

Guldan, S ;

Rudolf, D ;

Delmastro, D ;

Santabarbara, P ;

Brettman, L .

LEUKEMIA, 2002, 16 (05) :861-864

[9] Variation in gene expression patterns in follicular lymphoma and the response to rituximab [J].

Bohen, SP ;

Troyanskaya, OG ;

Alter, O ;

Warnke, R ;

Botstein, D ;

Brown, PO ;

Levy, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (04) :1926-1930

[10] Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H [J].

Brett, S ;

Baxter, G ;

Cooper, H ;

Johnston, JM ;

Tite, J ;

Rapson, N .

IMMUNOLOGY, 1996, 88 (01) :13-19

← 1 2 3 4 5 6 7 8 9 →